The impact of race and sex on metastatic bladder cancer survival

Urology ◽  
2021 ◽  
Author(s):  
Amr Mahran ◽  
April Millera ◽  
Adam Calaway ◽  
Megan Prunty ◽  
Camilo Arenas-Gallo ◽  
...  
2008 ◽  
Vol 9 (5) ◽  
pp. 493-501 ◽  
Author(s):  
Robert J. Oakland ◽  
Navin R. Furtado ◽  
Jake Timothy ◽  
Richard M. Hall

Object The vertebral column is the most common site for secondary bone metastases and lesions arising from hematological malignancies such as multiple myeloma (MM). These infiltrations can be lytic in nature and cause severe weakening of the vertebral body, an increased risk of fracture, and spinal cord compression leading to neurological deficit. Qualitatively it is apparent that increasing infiltration of these lytic lesions will have a deleterious effect on the mechanical behavior of the vertebrae. However, there is little quantitative information about the relationship between tumor deposits and the impact on the mechanical behavior of the vertebrae. In addition, there have been limited biomechanical assessments of the use of vertebroplasty in the management of these malignancies. The purpose of this preliminary study was to evaluate the mechanical behavior of lesion-infiltrated vertebrae from 2 malignant cancers and to investigate the effectiveness of vertebroplasty with and without tumor debulking. Methods Individual vertebrae from 2 donor spines—one with MM and another with bone metastases secondary to bladder cancer—were fractured under an eccentric flexion load, from which failure strength and stiffness were derived. Alternate vertebrae defined by spinal level were assigned to 2 groups: Group 1 involved removal of lesion material with Coblation (ArthroCare Corp.) preceding vertebroplasty; Group 2 received no Coblation prior to augmentation. All vertebrae were fractured postaugmentation under the same loading protocol. Micro-CT assessments were undertaken to investigate vertebral morphology, fracture patterns, and cement distribution. Results Multiple myeloma involvement was characterized by several small lesions, severe bone degradation, and multiple areas of vertebral shell compromise. In contrast, large focal lesions were present in the vertebrae with metastatic bladder cancer, and the shell generally remained intact. The mean initial failure strength of the vertebrae with metastases secondary to MM was significantly lower than in vertebrae with bone metastases secondary to bladder cancer (Load = 950 ± 300 N vs 2200 ± 750 N, p < 0.0001). A significant improvement in relative fracture strength was found postaugmentation for both lesion types (1.4 ± 0.5, p < 0.001). Coblation provided a marginally significant increase in the same parameter postaugmentation (p = 0.08) and qualitatively improved the ease of injection and guidance of cement. Conclusions In the vertebral column, metastatic lesions secondary to bladder cancer and MM showed variations in the pattern of infiltration, both of which led to significant reductions in fracture strength. Account should be taken of these differences to optimize the vertebroplasty intervention in terms of the cement formulation, delivery, and any additional surgical procedure.


2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e16023-e16023
Author(s):  
Anuradha Kunthur ◽  
Eric R Siegel ◽  
Rangaswamy Govindarajan

e16023 Background: Background: Cisplatin and gemcitabine combination chemotherapy is the standard regimen used for the treatment of metastatic bladder cancer. Most Veterans Administration (VA) patients with metastatic bladder cancer are elderly or with poor renal function, and are considered not good candidates for cisplatin administration. It is a common practice to substitute carboplatin for cisplatin in this population. Methods: Methods: We identified stage IV bladder cancer patients treated initially with cisplatin plus gemcitabine (Ci+G) or carboplatin plus gemcitabine (Ca+G) at VA medical centers from 2000 to 2010. The data was obtained via the VA central cancer registry from all VA medical centers across the country. Overall survival (OS) was summarized as Kaplan-Meier medians and compared for difference between platinum groups via Cox regression. Results: Results: 196 subjects () with stage IV bladder cancer were identified. There were 194 males , 78 received Ca+G, 118 received Ci+G. 149 deaths occurred during 197.49 person-years of follow up, for a median OS of 10.35 months. Median OS was 11.14 months with Ca+G versus 10.35 months with Ci+G. Cox regression revealed nearly equal group mortality rates, with Ca+G having a hazard ratio (90% confidence limits) of 1.02 (0.77–1.34) compared to Ci+G ( P= 0.93). Conclusions: Conclusion: Patients treated with Ca+G and Ci+G regimens had similar median OS, supporting the substitution of carboplatin for cisplatin with gemcitabine in this patient population.


2012 ◽  
Vol 187 (4S) ◽  
Author(s):  
Karim Chamie ◽  
Jeffrey C. Bassett ◽  
Timothy J. Daskivich ◽  
Meryl Leventhal ◽  
Dennis Deapen ◽  
...  

2015 ◽  
pp. 206-220
Author(s):  
David D Chism ◽  
Andrea B Apolo ◽  
Matthew I Milowsky

2021 ◽  
Vol 9 ◽  
pp. 232470962110356
Author(s):  
Balraj Singh ◽  
Parminder Kaur ◽  
Sachin Gupta ◽  
Nirmal Guragai ◽  
Michael Maroules

Bladder cancer is the most common urinary tract malignancy. Platinum-based chemotherapy is the first line of treatment in locally advanced or metastatic bladder cancer. Immunotherapy has become a novel therapy option in a broad variety of malignancies including bladder cancer. Immunotherapy is approved as first line of treatment in patients who are ineligible for platinum-based chemotherapy and second-line treatment for metastatic urothelial cancer who progressed after platinum-based treatments. We present the case of an 83-year-old female with metastatic bladder cancer who was chemotherapy ineligible and had complete response with immune checkpoint inhibitor pembrolizumab.


Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 351
Author(s):  
Massimiliano Creta ◽  
Giuseppe Celentano ◽  
Luigi Napolitano ◽  
Roberto La Rocca ◽  
Marco Capece ◽  
...  

Bladder cancer (BCa) is an endocrine-related tumour and the activation of androgen signalling pathways may promote bladder tumorigenesis. We summarized the available preclinical and clinical evidence on the implications of the manipulation of androgen signalling pathways on the outcomes of BCa therapies. A systematic review was performed in December 2020. We included papers that met the following criteria: original preclinical and clinical research; evaluating the impact of androgen signalling modulation on the outcomes of BCa therapies. Six preclinical and eight clinical studies were identified. The preclinical evidence demonstrates that the modulation of androgen receptor-related pathways has the potential to interfere with the activity of the Bacillus Calmette Guerin, doxorubicin, cisplatin, gemcitabine, and radiotherapy. The relative risk of BCa recurrence after transurethral resection of the bladder tumour (TURBT) is significantly lower in patients undergoing therapy with 5 alpha reductase inhibitors (5-ARIs) or androgen deprivation therapy (ADT) (Relative risk: 0.50, 95% CI: 0.30–0.82; p = 0.006). Subgroup analysis in patients receiving 5-ARIs revealed a relative risk of BCa recurrence of 0.46 (95% CI: 0.22–0.95; p = 0.040). A significant negative association between the ratio of T1 BCa patients in treated/control groups and the relative risk of BCa recurrence was observed. Therapy with 5-ARIs may represent a potential strategy aimed at reducing BCa recurrence rate, mainly in patients with low stage disease. Further studies are needed to confirm these preliminary data.


2021 ◽  
Vol 71 ◽  
pp. 101881
Author(s):  
Therese M.-L. Andersson ◽  
Tor Åge Myklebust ◽  
Mark J. Rutherford ◽  
Bjørn Møller ◽  
Isabelle Soerjomataram ◽  
...  

2021 ◽  
Vol 79 ◽  
pp. S631
Author(s):  
M.C. Hupe ◽  
M.J.P.. Hennig ◽  
S. Lokeshwar ◽  
S.L. Hasanali ◽  
D.S. Morera ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document